%0 Journal Article
%T Retinal angiotensin II and angiotensin
%A Firouz Daneshgari
%A Joe G Hollyfield
%A John W Peterson
%A K Bridget Brosnihan
%A Preenie deS Senanayake
%A Sadashiva S Karnik
%A Vera L Bonilha
%A Yoshiro Yamada
%J Journal of the Renin
%@ 1752-8976
%D 2018
%R 10.1177/1470320318789323
%X Hyperglycemia decreases angiotensin-(1-7), the endogenous counter-regulator of angiotensin II in the retina. The distribution and levels of retinal angiotensin II (Ang II) and angiotensin-(1-7) (Ang-(1-7)) were evaluated by confocal imaging and quantitative immunohistochemistry during the development of streptozotocin-induced diabetes in rats. In the nondiabetic eye, Ang II was localized to the endfeet of M¨šller cells, extending into the cellular processes of the inner plexiform layer and inner nuclear layer; Ang-(1-7) showed a wider distribution, extending from the foot plates of the M¨šller cells to the photoreceptor layer. Eyes from diabetic animals showed a higher intensity and extent of Ang II staining compared with nondiabetic eyes, but lower intensity with a reduced distribution of Ang-(1-7) immunoreactivity. Treatment of the diabetic animals with the angiotensin-converting enzyme inhibitor (ACEI) captopril showed a reduced intensity of Ang II staining, whereas increased intensity and distribution were evident with Ang-(1-7) staining. These studies reveal that pharmacological inhibition with ACEIs may provide a specific intervention for the management of the diabetes-induced decline in retinal function, reversing the profile of the endogenous angiotensin peptides closer to the normal condition
%K Angiotensin II
%K angiotensin-(1-7)
%K angiotensin-converting enzyme
%K diabetes
%K blindness
%K retinopathy
%U https://journals.sagepub.com/doi/full/10.1177/1470320318789323